SALT LAKE CITY--(BUSINESS WIRE)--Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, announced today that it has authorized management at its discretion to settle certain cashless exercises of its Series C Warrants using cash rather than shares, as allowed under the terms of the Series C Warrants. The Series C Warrants were issued as part of the Units of the Company that recently separated and de-listed from NASDAQ. “Great Basin remains on plan with all 2015 and early 2